Angiotech takes knotless Quill wound closing device to the US
This article was originally published in Clinica
Executive Summary
Angiotech Pharmaceuticals has launched in the US wound closure market its Quill self-retaining system (SRS), a product that eliminates the need for knots while providing improved tissue approximation, according to the Vancouver, Canada-based firm. With Quill, tiny opposing barbs are cut into the suture filament, catching tissue at numerous points on both sides of the surgical incision, which in turn spreads the retention force of the suture to provide a strong anchor with evenly distributed tension. Angiotech believes the product could reduce procedure times, resulting in hospital cost-savings and shorter procedure times. Angiotech says that the US wound closure market is worth around $1.7bn. During 2007, Angiotech plans to pursue CE marking and regulatory approvals for the product outside the US.